根据3月2日提交至美国证券交易委员会（SEC）的文件显示，Beam Therapeutics Inc.已与Bio Palette公司共同决定终止双方于2019年3月27日签订的授权协议。该协议的终止经双方协商一致，具体条款及后续安排未在申报文件中详细披露。此次变动标志着两家公司在基因编辑疗法领域的合作正式画上句号。
根据3月2日提交至美国证券交易委员会（SEC）的文件显示，Beam Therapeutics Inc.已与Bio Palette公司共同决定终止双方于2019年3月27日签订的授权协议。该协议的终止经双方协商一致，具体条款及后续安排未在申报文件中详细披露。此次变动标志着两家公司在基因编辑疗法领域的合作正式画上句号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.